Role of botulinum toxin type-A (BTX-A) in the management of trigeminal neuralgia

Pain Research and Treatment

Volumn 2013, Issue , 2013, Pages

  Verma, Gaurav ^a  

^a Himachal Pradesh   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84886459187     PISSN: 20901542     EISSN: 20901550     Source Type: Journal    
DOI: 10.1155/2013/831094     Document Type: Review

References (43)

1. Bagheri S. C., Farhidvash F., Perciaccante V. J., Diagnosis and treatment of patients with trigeminal neuralgia. Journal of the American Dental Association 2004 135 12 1713 1717 2-s2.0-11844281548 (Pubitemid 40090655)
2. Dufour S. K., An unusual case of stabbing eye pain: a case report and review of trigeminal neuralgia. Optometry 2002 73 10 626 634 2-s2.0-0036782299
3. Chole R., Patil R., Degwekar S. S., Bhowate R. R., Drug treatment of trigeminal neuralgia: a systematic review of the literature. Journal of Oral and Maxillofacial Surgery 2007 65 1 40 45 2-s2.0-33845380103 10.1016/j.joms.2005. 12.063 (Pubitemid 44894686)
4. Scrivani S. J., Mathews E. S., Maciewicz R. J., Trigeminal neuralgia. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology 2005 100 5 527 538 2-s2.0-26944450928 10.1016/j.tripleo.2005.06.004 (Pubitemid 41483634)
5. Lowe N. J., Botulinum toxin type A for facial rejuvenation: United States and United Kingdom perspectives. Dermatologic Surgery 1998 24 11 1216 1218 2-s2.0-0031784963 (Pubitemid 28533289)
6. Product Information Package Insert (71390US12J), Irvine, Calif, Allergen, Inc, 2002
7. Carruthers A., Kiene K., Carruthers J., Botulinum a exotoxin use in clinical dermatology. Journal of the American Academy of Dermatology 1996 34 5 I 788 797 2-s2.0-0029918076 10.1016/S0190-9622(96)90016-X (Pubitemid 26137205)
8. Matarasso S. L., Complications of botulinum A exotoxin for hyperfunctional lines. Dermatologic Surgery 1998 24 11 1249 1254 2-s2.0-0031782357 (Pubitemid 28533295)
9. Lange D. J., Rubin M., Greene P. E., Kang U. J., Moskowitz C. B., Brin M. F., Lovelace R. E., Fahn S., Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle and Nerve 1991 14 7 672 675 2-s2.0-0025863552
10. Matarasso A., Deva A. K., Botulinum toxin. Plastic and Reconstructive Surgery 2002 109 3 1191 1197 2-s2.0-0036198554 (Pubitemid 34206271)
11. Blitzer A., Binder W. J., Boyd W. J., Management of Facial Lines and Wrinkles 2000 Philadelphia, Pa, USA Lipincott Williams & Wilkins
12. Scott A. B., Simpson L., Clostridial toxins as therapeutic agents. Botulinum Neurotoxin and Tetanus Toxin 1989 New York, NY, USA Academic Press 399 406
13. Jankovic J., Brin M. F., Therapeutic uses of botulinum toxin. The New England Journal of Medicine 1991 324 17 1186 1194 2-s2.0-0025857556
14. Klein A. W., The therapeutic potential of botulinum toxin. Dermatologic Surgery 2004 30 3 452 455 2-s2.0-1942439990 10.1111/j.1524-4725.2004.30118.x (Pubitemid 38524173)
15. Mense S., Neurobiological basis for the use of botulinum toxin in pain therapy. Journal of Neurology 2004 251 supplement 1 1 7 2-s2.0-1542344497 (Pubitemid 38299759)
16. Costigan M., Woolf C. J., Pain: molecular mechanisms. Journal of Pain 2000 1 3 35 44 2-s2.0-0033830198 10.1054/jpai.2000.9818
17. Woolf C. J., Costigan M., Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proceedings of the National Academy of Sciences of the United States of America 1999 96 14 7723 7730 2-s2.0-0033529324 10.1073/pnas.96.14.7723 (Pubitemid 29328348)
18. Woolf C. J., Mannion R. J., Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999 353 9168 1959 1964 2-s2.0-0033526651 10.1016/S0140-6736(99)01307-0 (Pubitemid 29255720)
19. Borodic G. E., Acquadro M. A., The use of botulinum toxin for the treatment of chronic facial pain. Journal of Pain 2002 3 1 21 27 2-s2.0-0036175202 10.1054/jpai.2002.27142 (Pubitemid 34163487)
20. Sycha T., Graninger M., Auff E., Schnider P., Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study. European Journal of Clinical Investigation 2004 34 4 312 313 2-s2.0-2142704322 10.1111/j.1365-2362.2004. 01324.x (Pubitemid 38553602)
21. Aurora S., Botulinum toxin type A for the treatment of migraine. Expert Opinion on Pharmacotherapy 2006 7 8 1085 1095 2-s2.0-33745459807 10.1517/14656566.7.8.1085 (Pubitemid 43949946)
22. Wheeler-Aceto H., Porreca F., Cowan A., The rat paw formalin test: comparison of noxious agents. Pain 1990 40 2 229 238 2-s2.0-0025014877 10.1016/0304-3959(90)90073-M (Pubitemid 20070791)
23. Carlton S. M., Hargett G. L., Coggeshall R. E., Localization and activation of glutamate receptors in unmyelinated axons of rat glabrous skin. Neuroscience Letters 1995 197 1 25 28 2-s2.0-0029052635 10.1016/0304-3940(95) 11889-5
24. Türk Ü., Ilhan S., Alp R., Sur H., Botulinum toxin and intractable trigeminal neuralgia. Clinical Neuropharmacology 2005 28 4 161 162 2-s2.0-23644431890 10.1097/01.wnf.0000172497.24770.b0 (Pubitemid 41134241)
25. Durham P. L., Cady R., Cady R., Blumenfeld A. J., Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004 44 1 35 43 2-s2.0-1642568305 10.1111/j.1526-4610.2004.04007.x (Pubitemid 38116660)
26. Rapp D. E., Turk K. W., Bales G. T., Cook S. P., Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. Journal of Urology 2006 175 3 1138 1142 2-s2.0-32044462256 10.1016/S0022- 5347(05)00322-8 (Pubitemid 43200117)
27. Borodic G. E., Acquadro M., Johnson E. A., Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opinion on Investigational Drugs 2001 10 8 1531 1544 2-s2.0-0034895356 10.1517/13543784.10.8.1531 (Pubitemid 32717333)
28. Sheffer A. L., Soter N. A., McFadden E. R. Jr., Austen K. F., Exercise-induced anaphylaxis: a distinct form of physical allergy. Journal of Allergy and Clinical Immunology 1983 71 3 311 316 2-s2.0-0020700835 (Pubitemid 13160835)
29. Soter N. A., Wasserman S. I., Austen K. F., McFadden E. R. Jr., Release of mast-cell mediators and alterations in lung function in patients with cholinergic urticaria. The New England Journal of Medicine 1980 302 11 604 608 2-s2.0-0018896485 (Pubitemid 10073409)
30. Boghen D., Flanders M., Effectiveness of botulinum toxin in the treatment of spasmodic torticollis. European Neurology 1993 33 3 199 203 2-s2.0-0027414886 (Pubitemid 23099141)
31. Borodic G. E., Mills L., Joseph M., Botulinum A toxin for the treatment of adult-onset spasmodic torticollis. Plastic and Reconstructive Surgery 1991 87 2 285 289 2-s2.0-0026080776
32. Acquadro M. A., Borodic G. E., Treatment of myofascial pain with botulinum A toxin. Anesthesiology 1994 80 3 705 706 2-s2.0-0028348144 (Pubitemid 24097713)
33. Piovesan E. J., Teive H. G., Kowacs P. A., Della Coletta M. V., Werneck L. C., Silberstein S. D., An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 2005 65 8 1306 1308 2-s2.0-27144451747 10.1212/01.wnl.0000180940.98815.74 (Pubitemid 41508232)
34. Zúñiga C., Díaz S., Piedimonte F., Micheli F., Beneficial effects of botulinum toxin type a in trigeminal neuralgia. Arquivos de Neuro-Psiquiatria 2008 66 3 A 500 503 2-s2.0-52949097981
35. Wu C. J., Lian Y. J., Zheng Y. K., Botulinum toxin type A for the treatment of trigeminal neuralgias: results from a randomized, double-blind, placebo-controlled trial. Cephalgia 2012 32 6 443 450
36. Ngeow W. C., Nair R., Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology 2010 109 3 e47 e50 2-s2.0-77249157840 10.1016/j.tripleo.2009.03.021
37. Allam N., Brasil-Neto J. P., Brown G., Tomaz C., Injections of botulinum toxin type A produce pain alleviation in intractable trigeminal neuralgia. Clinical Journal of Pain 2005 21 2 182 184 2-s2.0-14044257232 10.1097/00002508-200503000-00010 (Pubitemid 40280233)
38. Headache Classification Committee of the International Headache Society, The international classification of headache disorders. Cephalgia 2004 1 1 1 152
39. Nurmikko T., Cruccu G., Botulinum toxin for trigeminal neuralgia. European Journal of Neurology 2009 16 5 e104 2-s2.0-64149096065 10.1111/j.1468-1331.2009.02583.x
40. Dworkin R. H., Turk D. C., Farrar J. T., Haythornthwaite J. A., Jensen M. P., Katz N. P., Kerns R. D., Stucki G., Allen R. R., Bellamy N., Carr D. B., Chandler J., Cowan P., Dionne R., Galer B. S., Hertz S., Jadad A. R., Kramer L. D., Manning D. C., Martin S., McCormick C. G., McDermott M. P., McGrath P., Quessy S., Rappaport B. A., Robbins W., Robinson J. P., Rothman M., Royal M. A., Simon L., Stauffer J. W., Stein W., Tollett J., Wernicke J., Witter J., Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005 113 1-2 9 19 2-s2.0-19944381491 10.1016/j.pain.2004.09.012 (Pubitemid 40038441)
41. Zakrzewska J. M., Lopez B. C., Kondziolka D., Haines S. J., Meyerson B., Quality of reporting in evaluations of surgical treatment of trigeminal neuralgia: recommendations for future reports. Neurosurgery 2003 53 1 110 122 2-s2.0-0038048497 (Pubitemid 36801514)
42. Zakrzewska J. M., Cohen J., Brown J., Alksne J., Gemillion H., Linskey M., Sirois D., Pollock B., An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 2006 66 9 1458 1459 2-s2.0-33646688472 (Pubitemid 43739682)
43. Voller B., Sycha T., Gustorff B., Schmetterer L., Lehr S., Eichler H. G., Auff E., Schnider P., A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 2003 61 7 940 944 2-s2.0-0141993854 (Pubitemid 37248649)